Skip to main content

Venous and Arterial Thromboembolism among New Users of NuvaRing and Other Combined Hormonal Contraceptives: A Descriptive Analysis

    Basic Details
    Date Posted
    Medical Product
    combined hormonal contraceptives (CHCs)
    ethinyl estradiol (EE)
    Health Outcome(s)
    arterial thromboembolism (ATE)
    venous thromboembolism (VTE)

    In this report we examined the characteristics of new users of NuvaRing and other combined hormonal contraceptives (oCHCs) with less than or equal to 20 mcg of ethinyl estradiol (EE) and conducted risk assessment for venous thromboembolism (VTE) and arterial thromboembolism (ATE) in the Sentinel Distributed Database (SDD).

    The study period includes data from January 1, 2014 to December 31, 2019. We distributed this request to 15 Data Partners on July 29, 2020.

    Additional Details
    FDA Center
    Time Period
    January 1, 2014 - December 31, 2019
    Analysis Type
    Population / Cohort
    Females 21 years of age and older
    Data Sources
    Sentinel Distributed Database (SDD)